UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2026

---

Anteris Technologies Global Corp.

(Exact name of registrant as specified in its charter)

---

Registrant’s telephone number, including area code: +61 7 3152 3200

Not Applicable

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

Appointment of Chief Financial Officer

On September 4, 2026, Anteris Technologies Global Corp. (the “Company”) appointed Brent Moen as its Chief Financial Officer, effective September 11, 2026.

Mr. Moen, age 59, is an experienced financial executive with more than 25 years of leadership experience, including Chief Financial Officer roles at both public and private companies. He has extensive expertise in capital markets, investor relations, mergers and acquisitions, and scaling growth-oriented organizations, including medical technology companies. Mr. Moen previously served as Chief Financial Officer of LifeLens Technologies from September 2023 to March 2026, Chief Financial Officer of Tactile Systems Technology from September 2018 to April 2023, and Chief Financial Officer of Entellus Medical from May 2016 to March 2018.  Mr. Moen holds a Bachelor of Accountancy from the University of North Dakota.

In connection with his appointment as Chief Financial Officer, the Company entered into an employment agreement, effective as of September 11, 2026, with Mr. Moen, which provides for the following: (1) an annual base salary of $475,000, (2) a short-term target annual bonus opportunity of up to 50% of his base salary (prorated for 2026), subject to performance metrics established by the Company’s Board of Directors or the Compensation Committee (the “Committee”) of the Board of Directors, (3) eligibility to participate in the Company’s long-term incentive plan and receive annual long-term incentive compensation awards (including a 2026 calendar year long-term incentive compensation award with a total target value of $500,000), and (4) eligibility to participate in other employee benefit plans generally available to senior executives of the Company from time to time. With respect to the 2026 long-term incentive compensation award, the Committee approved the grant to Mr. Moen, effective September 11, 2026 (the “Date of Grant”), under the Anteris Technologies Global Corp. Equity Incentive Plan of nonqualified stock options with a target value of $500,000 and an exercise price equal to the fair market value of a share of the Company’s common stock on the Date of Grant. This award will generally vest in substantially equal installments on each of the first three anniversaries of the Date of Grant and have a 10-year term.

Mr. Moen’s employment agreement also provides that he will be eligible for severance benefits, including nine months of base salary continuation and, if he elects continuation coverage under the Company’s medical plan pursuant to COBRA, reimbursement of 100% of his COBRA premiums for up to nine months, in each case upon termination of his employment by the Company without cause and subject to execution of a release of claims. The employment agreement also contains obligations of Mr. Moen regarding confidentiality, non-solicitation, and invention assignment.

The foregoing description of Mr. Moen’s employment agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

Mr. Moen will also enter into the Company’s standard form of indemnification agreement.

Transition of Matthew McDonnell

Effective as of September 11, 2026, Matthew McDonnell will commence service as the Company’s Head of Australia and will cease to serve as Chief Financial Officer of the Company. As Head of Australia, Mr. McDonnell will continue as an employee of the Company under his current compensation and benefit arrangements.

The following exhibits are filed with this Current Report on Form 8-K:

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.